Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Thursday, 23 March 2023, 12:30 HKT/SGT
Share:
    

Source: Eisai
Eisai to Present New Lecanemab Data, Including Research Evaluating Safety Profile, Clinical Outcomes and Quality of Life Measures, as Well as Other Important Alzheimer's Disease Research, at the AD/PD 2023 Annual Meeting
Presentations Explore ARIA with the Use of Antiplatelets or Anticoagulants and Isolated ARIA-H in Patients from Eisai's Lecanemab Phase 3 Confirmatory Clarity AD Study in Early Alzheimer's Disease

TOKYO, Mar 23, 2023 - (JCN Newswire) - Eisai Co., Ltd. announced today the company will present the latest findings on lecanemab (generic name, U.S. brand name: LEQEMBI), Eisai's anti-amyloid beta (Aβ) protofibril* antibody for the treatment of Alzheimer's disease (AD), at the 2023 International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders (AD/PD) from March 28-April 1 in Gothenburg, Sweden and virtually. Eisai will present new findings from the company's large, global Phase III confirmatory study of lecanemab, Clarity AD, including research into the management and monitoring of amyloid-related imaging abnormalities (ARIA) and health-related quality of life (HRQoL) measures. Eisai will also host a symposium, titled "Patient Clinical Care Pathway in Alzheimer's disease: Dialogue Amongst Experts," which will address the evolving landscape in AD. The lecanemab data and additional research findings from Eisai's AD portfolio will be featured in 11 presentations, including seven oral and four poster presentations.

"Our latest research examines the real-world outcomes based on lecanemab's impact on clinical results and safety, including its effect on health-related quality of life. Through our ongoing research, we hope to help simplify the patient journey and improve the lives of those living with Alzheimer's disease," said Michael Irizarry, M.D., Deputy Chief Clinical Officer and Senior Vice President of Clinical Research at Eisai Inc. "In addition to lecanemab, Eisai is presenting on several other key issues that will shape the future of Alzheimer's disease and brain health, including the next generation of clinical care and diagnostic pathways, exploration of unique populations affected by the disease, and accelerating drug development. We look forward to sharing our latest findings, including new insights from Eisai's Clarity AD trial of lecanemab, with the scientific community at AD/PD 2023."

Key Eisai Lecanemab and AD Presentations

- Two presentations related to ARIA in the Clarity AD trial will be presented during an oral session on Thursday, March 30:
> An analysis evaluating the use of antiplatelet and anticoagulant drugs in patients who experienced ARIA.
> An analysis of isolated ARIA-H events in the Clarity AD trial.

- Research evaluating caregiver burden and HRQoL across multiple scales using Clarity AD data will be presented during an oral session on Thursday, March 30.

- Research studying the characterization of Aβ protofibrils and the unique binding properties and mechanisms of Aβ clearance of lecanemab on Friday, March 31.

- Designing The Next Generation Clinical Care and Diagnostic Pathway for Alzheimer's Disease: A presentation focused on a new pathway which interweaves clinical, biological and digital assessments to guide an individualized AD patient journey on Friday, March 31.

Eisai Symposium - Patient Clinical Care Pathway in AD: Dialogue Amongst Experts
Eisai is sponsoring a symposium featuring three prominent clinical experts in the field of AD, Dr. Alireza Atri, Dr. Sharon Cohen and Dr. Lutz Frolich, who will provide insights on the AD landscape, evolving diagnostic workflow, identifying appropriate patients, and addressing patient needs on Wednesday, March 29. The session aims to provide guidance on the clinical management of patients and drive effective communication between physicians and patients.

Eisai serves as the lead of lecanemab development and regulatory submissions globally with both Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making authority.

* Protofibrils are large Aβ aggregated soluble species of 75-5000 Kd.1

Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120

Eisai Europe, Ltd.
(Europe, Australia, New Zealand and Russia)
EMEA Communications Department
+44 (0) 786 601 1272
EMEA-comms@eisai.net

Eisai, Inc. (U.S.)
Libby Holman
+1-201-753-1945
Libby_Holman@eisai.com

For more information, visit www.eisai.com/news/2023/news202321.html.


Topic: Press release summary
Source: Eisai

Sectors: BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2023 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Eisai
May 26, 2023 13:15 HKT/SGT
LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Demonstrates Long-Term, Durable Survival Benefit Versus Sunitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma
May 25, 2023 20:02 HKT/SGT
Eisai's Initiatives for Developing New Medicines for Neglected Tropical Diseases and Malaria
May 24, 2023 17:03 HKT/SGT
Eisai Delivers New Data and Highlights Continued Progress of Oncology Portfolio and Pipeline at ASCO 2023
May 20, 2023 09:20 HKT/SGT
Eisai Submits Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease in Great Britain
May 16, 2023 08:27 HKT/SGT
Health Canada Accepts New Drug Submission for Lecanemab as Treatment for Early Alzheimer's Disease
May 8, 2023 10:15 HKT/SGT
Eisai Enters Into Joint Development Agreement with Blissbio for Antibody Drug Conjugate BB-1701 with Option Rights for Strategic Collaboration
Apr 6, 2023 17:32 HKT/SGT
Eisai Completes a Major Renovation of Tsukuba Research Laboratories
Apr 4, 2023 12:23 HKT/SGT
Eisai Publishes Long-Term Health Outcomes Using Simulation Model of Lecanemab Using Phase 3 Clarity Ad Data in Peer-Reviewed Neurology and Therapy Journal
Apr 3, 2023 12:06 HKT/SGT
Eisai Enters Into Agreement With National Cancer Center to Collaborate on Investigator-Initiated Clinical Research for Anticancer Agent Tazemetostat Based on "Patient-Proposed Healthcare Services" System
Mar 31, 2023 15:51 HKT/SGT
Eisai Presented New Analyses of Aria and QOL on Lecanemab in Clarity AD at the AD/PD 2023 Annual Meeting
More news >>
 News Alerts
Copyright © 2023 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: